FDA Grants Priority Review for PolyPid’s D-PLEX₁₀₀ Surgical Infection Prevention Drug
Event summary
- FDA accepted PolyPid’s NDA for D-PLEX₁₀₀ with Priority Review, setting a PDUFA target action date of November 28, 2026.
- No filing review issues were identified by the FDA, accelerating the review timeline to approximately six months.
- $15 million milestone payment from Azurity triggered, completing $30 million in upfront and near-term milestone payments under their commercial partnership.
- D-PLEX₁₀₀ aims to prevent surgical site infections (SSIs) with a 60% relative risk reduction demonstrated in Phase 3 SHIELD II trial.
The big picture
The FDA’s Priority Review designation for D-PLEX₁₀₀ underscores the urgency and potential impact of PolyPid’s innovation in surgical infection prevention. This development aligns with broader industry trends toward targeted, localized drug delivery systems aimed at reducing healthcare-associated infections. The strategic partnership with Azurity Pharmaceuticals positions PolyPid to capitalize on a significant commercial opportunity if regulatory approval is secured.
What we're watching
- Regulatory Approval
- Whether the FDA will approve D-PLEX₁₀₀ by the November 28, 2026 PDUFA target action date.
- Commercial Launch
- The pace at which Azurity can initiate a U.S. commercial launch of D-PLEX₁₀₀ in early 2027 if approved.
- Market Adoption
- How effectively D-PLEX₁₀₀ can penetrate the market for preventing surgical site infections, particularly in abdominal colorectal surgery.
Related topics